Today the signals point in two clear directions at once. The experts running these simulations put strong odds — around 74 percent — that the government keeps psychedelics in Schedule I, its most locked-down category of banned drugs, through the end of 2026. There will be no big, sweeping change in the law. At the same time, they see MDMA — the drug being tested to treat post-traumatic stress, the deep and lasting damage that trauma leaves behind — moving toward approval within a year. The likely outcome isn't a simple yes. It's a careful yes, with strict rules: only certified therapists could give it, in tightly controlled settings. And there's fresh weight behind that caution — deaths at unregulated ceremonies are hardening the resolve to keep any approved use safe and supervised.
Beneath the headlines, a pattern is taking shape. The wide-open door — legal psychedelics for everyone — stays shut. But a narrow, guarded door is swinging open, and it leads through the veterans. The strongest single prediction today, at 72 percent, is that a government-backed program giving veterans access to MDMA and psilocybin — the active ingredient in what people call magic mushrooms — could launch within eighteen months. This isn't an accident. Both political parties agree on almost nothing these days, but they agree on helping the people who served. Veterans are the wedge that moves everything else. Change won't come as one grand law. It will come one careful, proven step at a time, and the first step is being built for the people who sacrificed most.
For the human beings inside this story, the felt reality is a mix of hope and hard patience. Picture a veteran who has tried every standard treatment and still can't sleep through the night, still can't sit at the dinner table without bracing for a threat that isn't there. For that person, the difference between "someday" and "within eighteen months" is enormous. It is the difference between despair and a reason to hold on. The strict rules coming with approval aren't roadblocks — they're the guardrails that make sure this help is real, safe, and lasting, not another false promise. And the tragedies at unregulated ceremonies are a sober reminder of why doing this carefully matters: the goal isn't speed for its own sake, it's healing that holds.
The highest path genuinely open right now is not the loud one. It's the true one — a supervised, trusted program that proves this medicine works and works safely, starting with those who earned the right to be first in line. From there, the door widens.
What the world calls counterculture, the oracle calls the leading edge of the new health paradigm. The threads forming today will be tomorrow's standard of care.
What is being called in cannot be called back.
74%
Psilocybin, MDMA, and LSD stay illegal federally through 2026
The DEA (the US agency that classifies dangerous drugs) is not expected to move psilocybin, MDMA, or LSD out of their current 'Schedule I' status — the category reserved for substances the government considers highly dangerous with no accepted medical use. This matters because Schedule I status is the main reason these substances are so hard to research, prescribe, or access legally anywhere in the US.
→ There's a 74% chance all three major psychedelics stay fully federally illegal through December 31, 2026.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
DEA maintains Schedule I on core psychedelics through 2026; no broad rescheduling.. Enforcement priorities will not shift without an approved medical product and airtight diversion controls. DEA has taken no public rescheduling action on core psychedelics. || RESOLUTION RULE: YES if psilocybin, MDMA, and LSD all remain in Schedule I of the Controlled Substances Act as of 2026-12-31
68%
FDA may approve MDMA therapy but with tight controls on who can give it
If the FDA (Food and Drug Administration) approves MDMA as a therapy for PTSD, it would likely come with a REMS — a Risk Evaluation and Mitigation Strategy, which is essentially a strict rulebook that limits who can prescribe, administer, and monitor the drug. Think of it like approving a powerful painkiller only for certified pain clinics, not general practitioners. This would make access real but narrow.
→ There's a 68% chance the FDA approves MDMA therapy for PTSD by October 2026, but only through a tightly controlled, certified-provider system.
Resolves: 2026-10-14 · USA
REGULATORY
the precise call ▾
MDMA-PTSD reaches a favorable but conditional FDA outcome with a restrictive REMS within ~12 months.. Consensus of 4 agents (fda_reviewer, maps_researcher, investor, veteran_advocate). FDA has previously flagged REMS necessity for psychedelic therapies given supervised-administration requirements; conditional approval with REMS is the most probable path if any approval occurs. || RESOLUTION RULE: YE
55%
MDMA therapy for PTSD could get FDA approval within the next year
The FDA (Food and Drug Administration) could approve MDMA as a legal, prescribed therapy for PTSD (post-traumatic stress disorder) within the next 12 months. The clinical trial data is in, and there's political interest in helping veterans and trauma survivors. But the FDA could also reject the application — so this is far from certain.
→ There's a 55% chance — essentially a coin flip — that the FDA approves MDMA therapy for PTSD by July 2027.
Resolves: 2027-07-16 · USA
REGULATORY
the precise call ▾
MDMA-PTSD receives FDA approval within 12 months.. Phase 3 data and aligned political will make an approval decision plausible within the year, though CRL risk remains. This is the broadest, most consequential regulatory milestone. || RESOLUTION RULE: YES if the FDA approves any MDMA-assisted therapy product for PTSD (any label/REMS) on or before 20
72%
Congress won't hold a vote on legalizing psychedelics federally by 2026
Even if individual lawmakers support changing how the federal government classifies psychedelics, a full vote on the floor of the House or Senate is extremely unlikely by the end of 2026. Congress's schedule is packed, and the DEA (Drug Enforcement Administration) hasn't signaled support, which makes lawmakers reluctant to push it forward.
→ There's a 72% chance Congress holds zero floor votes on rescheduling psilocybin, MDMA, or LSD before the end of 2026.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
Broad federal rescheduling stalls through 2026 with no floor vote.. DEA is not aligned and the legislative calendar is packed. No chamber will hold a floor vote on core-psychedelic rescheduling absent a completed FDA approval. Historically no such bill has reached a floor vote. || RESOLUTION RULE: YES if no floor vote is held in either the U.S. House or Senate on le
70%
Government advisors will officially question how long MDMA therapy effects last
When the FDA (the US Food and Drug Administration) convenes a panel of outside experts to review MDMA as a therapy for PTSD (post-traumatic stress disorder), those experts are expected to formally raise questions about whether the treatment's benefits hold up over time. This matters because if relief fades quickly after treatment, it changes how useful or cost-effective the therapy really is.
→ There's a 70% chance that official FDA advisory committee documents will explicitly question how long MDMA therapy results last.
Resolves: 2027-03-01 · USA
RESEARCH
the precise call ▾
Durability/effect-longevity questions appear in the FDA advisory committee record for MDMA-PTSD.. Mechanistic uncertainty about durability is real and the FDA advisory panel has previously demanded explicit durability discussion; this is standard when long-term effect maintenance is unproven. || RESOLUTION RULE: YES if the official FDA advisory committee meeting materials or transcript for an MD